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Abstract
Background: Disseminated intravascular coagulation (DIC) after liver transplantation (LT) is a difficult complication.
We report a case of disseminated intravascular coagulation after deceased donor liver transplantation (DDLT)
treated with recombinant thrombomodulin (rTM).
Case presentation: A 30-year-old woman underwent right tri-segment split graft DDLT for acute liver failure. She
developed disseminated intravascular coagulation on post-operative day 5 with fever. Computed tomography
revealed necrosis of hepatic segment IV, and her acute-phase disseminated intravascular coagulation score was
seven points. She was given rTM, and the inflammation, liver function, and coagulation disorders immediately
improved. However, pleural effusion drainage from the chest tube became bloody on post-operative day 11, and
rTM was discontinued. She progressed well and was discharged from the hospital on post-operative day 28. rTM is
an effective treatment for disseminated intravascular coagulation; however, rTM for cases with coagulation
disorders, which can occur after liver transplantation, has both risks and benefits.
Conclusions: We report a case of DIC after LT, in which rTM was potentially effective. Further studies are needed to
determine the appropriate dosages, duration, and additional considerations for rTM therapy in liver transplantation
patients.
Keywords: Deceased donor liver transplantation, Split graft, Recombinant thrombomodulin, Disseminated
intravascular coagulation
Background
Split liver transplantation (LT) is one of few surgical
options to expand the donor pool and address organ
shortages and increasing wait list mortality rates [1].
However, split LT is associated with problems related
to the surgical technique and possible complications.
Hong et al. reported that the adult 10-year patient sur-
vival rate was significantly lower for split extended
right-liver graft compared with adult whole-liver and
living donor right-liver graft [2]. Halac et al. showed
that the most frequent complications in split LT were bil-
iary complications, followed by vascular complications
and segment IV necrosis [3]. These complications could
lead to disseminated intravascular coagulation (DIC) and
poor outcomes after split LT.
Recombinant thrombomodulin (rTM) has excellent
anticoagulant activity and is a known therapy for DIC.
Recent reports have shown the superiority of rTM over
low-dose heparin for treating DIC and that rTM has sev-
eral activities, including anti-inflammatory effects as well
as its anticoagulant activity [4].
We present a patient with DIC who was treated with
rTM after deceased donor liver transplantation (DDLT)
with right tri-segment split graft.
Case presentation
The patient was a 30-year-old female with jaundice.
Blood analysis at a local hospital revealed severe liver
failure, and she was transferred to our hospital. She was
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diagnosed as having acute liver failure of unknown
etiology and underwent medical treatment, including
plasma exchange and transfusion; however, her liver
function did not improve. LT was planned, but there
was no suitable living donor, and she was placed on the
DDLT wait list. DDLT was performed with right tri-
segment split graft 13 days later. At the time of abdom-
inal closure, the transplanted graft showed ischemia in
segment IV. The graft volume to the standard liver vol-
ume ratio was 123.4 % (graft volume = 1381 g), the cold
ischemic time was 10 h and 32 min, the warm ischemic
time was 50 min, and the anhepatic time was 1 h and
5 min. The native liver showed subtotal necrosis.
Although no severe complications occurred after sur-
gery, she developed a fever and increased total bilirubin
level on post-operative day (POD) 5 (Fig. 1). Blood
analysis revealed decreased platelets, coagulation ab-
normalities, and severe inflammation. Computed tom-
ography on POD 6 revealed necrosis of segment IV of
the transplanted graft (Fig. 2). She was diagnosed as
having DIC based on the Japanese acute-phase DIC
score (seven points) [5], and rTM was begun at 380 U/
kg/day. Thereafter, inflammation, liver function, and
coagulation abnormalities dramatically improved and
the fever resolved (Figs. 1 and 3). However, on POD 12,
the pleural effusion drainage from the chest tube be-
came bloody. The anticoagulant effect of rTM was con-
sidered the cause and was discontinued. On POD 14,
the pleural effusion drainage became serous, and on
POD 19, the quantity of pleural effusion was minimal
and the chest tube was removed. Thereafter, she made
good progress and was discharged from hospital on
POD 28.
Discussion
rTM was effective for DIC after DDLT with right tri-
segment split graft in this case, and we believe that ne-
crosis of segment IV of the split graft caused the DIC.
DIC is a severe possible complication after LT and is a
systemic disorder characterized by continuous intravas-
cular coagulation related to an underlying disease. The
liver produces most of the body’s coagulation factors,
fibrinolytic compounds, and coagulation inhibitor fac-
tors. However, the dramatic coagulation disorders and
fibrinolysis seen with DIC occur systemically after liver
transplantation. Coagulation and fibrinolysis are markedly
degraded in end-stage liver failure patients well before
surgery, and these functions are degraded further after
surgery because of the intra-operative anhepatic time and
delayed time to improved graft function. After transplant-
ation, the competing effects of acute inflammation with
coagulation and fibrinolysis lead to thrombotic microangi-
opathy and systemic inflammatory response syndrome
making it difficult to grasp the disease symptoms and
treatment [6].
Cauley et al. [7] recently aimed to determine the current
risk of graft failure in adult recipients after split LT by ana-
lyzing data from the United Network for Organ Sharing
registry, assessing 889 split liver grafts performed from
1995 to 2010. Similar to previous analyses from the USA,
the authors noted a significantly increased risk of graft
failure in split grafts compared with whole grafts. In Japan,
Sakamoto et al. showed that complications related to the
operation were more frequent in split LT. They reported
that the occurrence of bile leakage in extended right-lobe
grafts was generally related to the viability of segment IV.


































Fig. 1 Post-operative changes in body temperature, total bilirubin levels, and alanine aminotransferase
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from the left-side vasculature, may be sacrificed during
the splitting procedure and may increase the risk of paren-
chymal necrosis and bile leakage with an incidence of
approximately 20–30 %. Segment IV-related complica-
tions may be directly associated with high rates of graft
loss and mortality [8]. These data might include cases that
develop DIC after surgery with necrotic areas in the graft,
as in our case. Post-operative DIC can also occur follow-
ing hepatectomy because liver partition and portal vein
ligation for staged hepatectomy can cause post-operative
ischemia in segment IV [9]. Monitoring hepatectomy pa-
tients for post-operative DIC is important with intra-
operative visible hepatic ischemia.
rTM is a novel anticoagulant agent composed of the ac-
tive, extracellular domain of thrombomodulin that regu-
lates the imbalanced coagulation system by reducing
excessive activation of thrombin [10]. In Japan, it has been
reported that rhTM potentially reduces the morbidity and
mortality in patients with sepsis-induced DIC [11–13].
Similarly, an international phase IIb clinical trial of rTM
in patients with sepsis and suspected DIC [14] suggested
that this treatment is both efficacious and safe, stimulating
enthusiasm for the application of rTM in critical care.
rTM also has an inhibitory effect on high-mobility group
box 1 (HMGB1) by an anti- inflammatory action [15].
HMGB1 is an intranuclear protein that was originally
identified as a DNA-binding protein but has since been
recognized as a late-phase mediator during sepsis [16].
HMGB1 is also known to act as a pro-coagulant as well as
a pro-inflammatory mediator for septic organ dysfunction.
Hepatocyte nuclei contain high levels of HMGB1, which
is released into the blood after ischemic-reperfusion injury
to the liver and hepatocyte necrosis [17]. Therefore, rTM
is a useful treatment for DIC after LT.
Conclusions
In conclusion, we report a case of DIC after DDLT with
right tri-segment split graft, in which rTM was potentially
effective. Further investigations are needed to confirm the




























Fig. 3 Japanese acute-phase DIC scores from on POD 5 to 12
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efficacy of rTM for DIC after LT and to consider rTM the
standard treatment for DIC in LT recipients.
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